Granulocyte Colony Stimulating Factor (G-CSF) can allow treatment with clozapine in a patient with severe Benign Ethnic Neutropaenia (BEN): A case report

Journal of Psychopharmacology

Volumn 26, Issue 9, 2012, Pages 1280-1282

  Spencer, Benjamin W J ^a   Williams, Hugh R J ^a   Gee, Siobhan H ^a   Whiskey, Eromona ^a,b   Rodrigues, Joseph P ^a,b   Mijovic, Aleksandar ^c   MacCabe, James H ^a,c  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

BEN; clozapine; G CSF; schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BECLOMETASONE; CALCIUM; CLOZAPINE; ESCITALOPRAM; GRANULOCYTE COLONY STIMULATING FACTOR; LITHIUM; NORCLOZAPINE; OLANZAPINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RISPERIDONE; SALBUTAMOL; VITAMIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGITATION; ARTICLE; ASTHMA; BENIGN ETHNIC NEUTROPENIA; BLOOD EXAMINATION; CASE REPORT; DRUG DOSE TITRATION; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG INTERACTIONS; DRUG MONITORING; DRUG RESISTANCE; GRANULOCYTE COLONY-STIMULATING FACTOR; GREAT BRITAIN; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTE COUNT; MALE; NEUTROPENIA; NEUTROPHILS; RECOMBINANT PROTEINS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864967601     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112450782     Document Type: Article

References (11)

1. Esposito D, Rouillon F, Limosin F. Continuing clozapine treatment despite neutropenia. Eur J Clin Pharmacol. 2005 ; 60: 759-764
2. Gerson SL, Gullion G, Yeh HS, et al. Granulocyte colony-stimulating factor for clozapine-induced agranulocytosis. Lancet. 1992 ; 340: 1097
3. Guy W ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ No Adm 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs ; 1976 :
4. Hagg S, Rosenius S, Spigset O. Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. Int Clin Psychopharmacol. 2003 ; 18: 173-174
5. Halter J, Kodera Y, Ispizua AU, et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica. 2009 ; 94: 94-101
6. Hsieh MM, Everhart JE, Byrd-Holt DD, et al. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Int Med. 2007 ; 146: 486-492
7. Hsieh MM, Tisdale JF, Rodgers GP, et al. Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy?. J Clin Oncol. 2010 ; 28: 1633-1637
8. Joffe G, Eskelinen S, Sailas E. Add-on filgrastim during clozapine rechallenge in patients with a history of clozapine-related granulocytopenia/ agranulocytosis. Am J Psychiatry. 2009 ; 166: 236
9. Mathewson KA, Lindenmayer JP. Clozapine and granulocyte colony-stimulating factor: potential for long-term combination treatment for clozapine-induced neutropenia. J Clin Psychopharmacol. 2007 ; 27: 714-715
10. Tigue CC, Mckoy JM, Evens AM, et al. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007 ; 40: 185-192
11. Whiskey E, Olofinjana O, Taylor D. The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study. J Psychopharmacol. 2011 ; 25: 842-845